

DOI: 10.29289/259453942019V29S1EP28

## PROGNOSTIC EVALUATION OF PATIENTS WITH LUMINAL B IMMUNOPHENOTYPE, SUBMITTED TO NEOADJUVANT CHEMOTHERAPY ATTENDED AT DR ARNALDO VIEIRA DE CARVALHO CANCER INSTITUTE FROM 2006 TO 2014

Fábio F. O. Rodrigues<sup>1</sup>, Eveline A. Silva<sup>1</sup>, Etienne A. Bastos<sup>1</sup>, Daniel C. B. de Oliveira<sup>1</sup>, Rodrigo M. Silva<sup>1</sup>, Carlos E. Fristachi<sup>1</sup>

<sup>1</sup>Oncogynecology and Mastology Service, Dr Arnaldo. Vieira de Carvalho Cancer Institute – São Paulo (SP), Brazil.

**Objectives:** Evaluate the characteristics of the patients with Luminal B breast cancer submitted to neoadjuvant chemotherapy, attended at the Oncogynecology and Mastology Service (SOGM, acronym in Portuguese) of Dr. Arnaldo Vieira de Carvalho Cancer Institute (ICAVC) from 2006 to 2014. **Methods:** A descriptive, retrospective, longitudinal study was performed with patients with invasive breast carcinoma attended at ICAVC in São Paulo; data were analyzed on the database of Microsoft Excel<sup>®</sup>. **Results:** 339 patients were evaluated, which 92 (27.1%) presented breast neoplasm with compatible immunohistochemistry with luminal B tumors; of these, 23 (25%) were submitted to neoadjuvant chemotherapy, 4 (17.4%) presented pathological complete response (pCR), both mammary and axillary, 2 (8.7%) patient presented distant metastasis for bone and 1 (4.3%) of them had local recurrence. The overall mean survival was 12 years and the disease-free survival was 5 years. **Conclusion:** The pCR was 17.4% in patients with luminal B tumors seen in our service, with high overall survival rates due to the possibility of adjuvancy with hormonal block, which is consistent with the data present in the current literature regarding the prognosis of such patients.